Effect of Gastric Bypass on the Absorption of Metformin
ABSORB-Met
1 other identifier
observational
34
1 country
1
Brief Summary
Background: Gastric bypass is the most commonly performed type of bariatric (obesity) surgery, has dramatically increased in popularity and is now considered to be preferred treatments in severely obese patients that fail non-surgical therapy - particularly in patients with type 2 diabetes. Drug malabsorption is a potential concern post-gastric bypass because intestinal length is reduced. Purpose: The purpose of this controlled, pharmacokinetic study is to determine whether the absorption of a single dose of metformin, the first line drug treatment in patients with type 2 diabetes, is significantly reduced after gastric bypass. Methods: A single dose of standard release metformin 1000 mg will be administered to patients who have undergone gastric bypass and to patients who have not received surgery but are on the wait list (wait-listed controls). Blood sampling and urine sampling will occur in standardized fashion over the ensuing 24 hours to measure and compare the absorption of metformin between study arms. 34 patients total will be recruited. Significance: Following completion of this study, we will better understand how gastric bypass affects metformin absorption. Ultimately, this information will help to ensure that this patient population is receiving optimal doses of this important drug treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2009
CompletedFirst Submitted
Initial submission to the registry
November 12, 2009
CompletedFirst Posted
Study publicly available on registry
November 13, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2010
CompletedMarch 3, 2011
March 1, 2011
November 12, 2009
March 2, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Area-under-the-curve of metformin absorption (0-infinity)
cross-sectional
Secondary Outcomes (5)
AUC (0-24h)
cross-sectional
tmax
cross-sectional
cmax
cross-sectional
AUC glucose (0-8h)
cross-sectional
bioavailability of metformin (urine metformin concentration from 0-infinity)
cross-sectional
Study Arms (2)
Post Gastric Bypass
Obese Controls
age, BMI, gender matched
Eligibility Criteria
Post gastric bypass and obese controls 1. Male and Female 2. 18 - 60 years old 3. ≥ 3 months post-RYGB surgery or wait listed for bariatric surgery 4. Able to provide written informed consent.
You may qualify if:
- Patients living within and around Edmonton that have been referred to the Alberta Health Services Weight Wise Program
You may not qualify if:
- Undergone or undergoing revision of a previous bariatric procedure
- Any major post-operative gastrointestinal complications, such as an anastomotic leak, outlet obstruction or persistent vomiting
- Currently on metformin therapy
- Any contraindications to metformin therapy such as:
- allergy to the drug
- chronic metabolic acidosis
- history of lactic acidosis
- liver failure or baseline liver enzymes higher than 3-fold above the upper limit of normal
- congestive heart failure
- renal failure (glomerular filtration rate \< 60 ml/min)
- alcoholism
- acute illness
- fatty liver disease
- Pregnant or nursing
- Not taking furosemide or nifedipine (both drugs may increase metformin absorption by 15-20%)the day of visit 2.
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Alberta Hospital Clinical Investigation Unity
Edmonton, Alberta, T6G2B7, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Raj Padwal, MD
University of Alberta
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 12, 2009
First Posted
November 13, 2009
Study Start
September 1, 2009
Study Completion
December 1, 2010
Last Updated
March 3, 2011
Record last verified: 2011-03